Navigation Links
ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering
Date:8/30/2007

FREMONT, Calif., Aug. 30 /PRNewswire/ -- ARYx Therapeutics, Inc. announced today that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission for a proposed initial public offering of shares of its common stock. All of the shares in the proposed offering will be sold by ARYx Therapeutics.

The underwriters of the offering will be Morgan Stanley & Co. Incorporated acting as sole book runner and lead manager and CIBC World Markets Corp., Jefferies & Company, Inc. and Leerink Swann & Co., Inc. acting as co-managers. The number of shares to be offered and the price range for the offering have not yet been determined.

The offering will be made only by means of a prospectus. When available, a copy of the preliminary prospectus relating to the offering may be obtained from Morgan Stanley & Co. Incorporated by emailing prospectus@morganstanley.com or by contacting the prospectus department at 180 Varick Street, New York, NY 10014 Attn: Prospectus Department.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

About ARYx Therapeutics, Inc.

ARYx Therapeutics is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates designed to eliminate known safety issues associated with well-established, commercially successful drugs. ARYx uses its RetroMetabolic Drug Design(TM) technology to design structurally unique molecules that retain the efficacy of these original drugs but are metabolized through a potentially safer pathway to avoid specific adverse side effects associated with these compounds. ARYx currently has three products in Phase 2 clinical trials: ATI-7505 for the treatment of various gastrointestinal disorders, ATI-5923 for the treatment of patients at risk for the formation of dangerous blood clots, and ATI-2042 for the treatment of atrial fibrillation.


'/>"/>
SOURCE ARYx Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. PCR Polymerases Application Profiles
3. RNAlater Preserves Bacterial Gene Expression Profiles for Array Analysis
4. Obtaining a contour map from multifiles or 3D data in DataMax
5. Successful stabilization of gene expression profiles
6. Madison biotech NimbleGen files for IPO; one of states best-funded firms
7. Third Wave files countersuit vs. Digene in patent case
8. TomoTherapy files registration statement for IPO
9. Merge files financial reports by market opening
10. The Why Files celebrates decade of science exploration
11. Third Wave files patent suits against Digene, Chiron and Bayer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... PARK, Calif. , Dec. 6, 2016 /PRNewswire/ ... up to $150 million from the National Institutes ... Diseases and the Division of AIDS (NIAID-DAIDS) to ... and other non-vaccine pre-exposure (PreP) agents. Under the ... of preclinical product development services for candidate HIV-prevention ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... discovery and development of precision treatments for neurodegenerative diseases, today announced the ... (AD) inhibited the direct neurotoxic effect of prion-like forms of Amyloid beta ...
(Date:12/5/2016)... , Dec. 5, 2016 Axovant Sciences Ltd. ... company focused on the treatment of dementia, today announced ... the treatment of Alzheimer,s disease will be presented at ... on Friday, December 9, 2016 in San ... results of both simple and complex measures of activities ...
(Date:12/5/2016)... , Dec 5, 2016 Research ... "Biomarkers - Technologies, Markets and Companies" to their offering. ... , , ... and their discovery using various -omics technologies such as proteomics and ... and new tests are also based on biomarker. Currently ...
Breaking Biology Technology:
(Date:11/16/2016)... SANTA CLARA, Calif. , Nov. 16, 2016 /PRNewswire/ ... company enhancing user experience and security for consumer ... provider for the financial and retail industry, today ... more secure and convenient way to authenticate users ... now uses Sensory,s TrulySecure™ software which ...
(Date:11/14/2016)... Inc. ("xG" or the "Company") (Nasdaq: XGTI, XGTIW), a ... challenging operating environments, announced its results for the third ... conference call to discuss these results on November 15, ... Key Recent Accomplishments The ... Vislink Communication Systems. The purchase is expected to close ...
(Date:6/22/2016)... -- The American College of Medical Genetics and Genomics was once ... one of the fastest-growing trade shows during the Fastest 50 ... Las Vegas . Winners ... each of the following categories: net square feet of paid ... The 2015 ACMG Annual Meeting was ranked 23 out of ...
Breaking Biology News(10 mins):